Sana Biotechnology Confirms Key Program Timelines and Announces Portfolio Prioritization
Expect to file IND this year for SC291 with potential clinical data in 2023
Expect to file INDs for SG295 and SC263 in 2023; SC451 and BCMA-targeted CAR T in 2024
Related news for (SANA)
- Biotech, Batteries & BioSilk—Bold Breakouts
- Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
- 24/7 Market News Snapshot 23 June, 2025 – Sana Biotechnology, Inc. Common Stock (NASDAQ:SANA)
- Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions
- Sana Biotechnology to Present at June 2025 Investor Conferences